GENETIC ANALYSIS NK -60 Total Liabilities
GENETIC ANALYSIS NK -60 total liabilities. Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has total liabilities worth €23.93 Million EUR (≈ $27.97 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8V8 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of GENETIC ANALYSIS NK -60 (2021–2025)
Total liabilities of GENETIC ANALYSIS NK -60 from 2021 to 2025. This chart illustrates how GENETIC ANALYSIS NK -60's total liabilities have evolved over time, based on quarterly financial data.
GENETIC ANALYSIS NK -60 Competitors by Total Liabilities
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tristel
LSE:TSTL
|
UK | GBX11.88 Million |
|
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
|
USA | $24.07 Million |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
India | Rs-182.41 Million |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
USA | $34.30 Million |
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
Sweden | Skr6.40 Million |
|
Golden Goliath Resources Ltd.
V:GNG
|
Canada | CA$389.98K |
|
Discovery Alaska Ltd
AU:DAF
|
Australia | AU$74.02K |
|
Silver Castle Holdings Ltd
TA:SLCL
|
Israel | ILA6.67 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down GENETIC ANALYSIS NK -60's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENETIC ANALYSIS NK -60 (8V8) total assets.
Liquidity & Leverage Metrics
GENETIC ANALYSIS NK -60 Total Liabilities Ratios Explained
GENETIC ANALYSIS NK -60 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENETIC ANALYSIS NK -60's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual total liabilities of GENETIC ANALYSIS NK -60 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €25.37 Million ≈ $29.66 Million |
+27.57% |
| 2024-12-31 | €19.88 Million ≈ $23.25 Million |
-7.48% |
| 2023-12-31 | €21.49 Million ≈ $25.13 Million |
+5.95% |
| 2022-12-31 | €20.28 Million ≈ $23.71 Million |
+77.93% |
| 2021-12-31 | €11.40 Million ≈ $13.33 Million |
-- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more